secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061631
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility
------------------------------------------------------------------------

- Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.
- Net loss available to common stockholders was $13.2M ($0.60 per share) vs $8.3M loss in Q1 2023.
- Closed $25M initial draw on up to $50M debt financing with OrbiMed; expects runway through end of 2024.
- Appointed Liselotte Hyveled, Chief Patient Officer at Novo Nordisk, to Board of Directors.
- Management reiterates full-year revenue growth guidance exceeding 50%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/0001104659-24-061631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/tm2414537d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer